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Objective: Metabolically healthy obese phenotype is deﬁned by high insulin sensitivity and lack of
metabolic syndrome, parameters regulated by omental adipose tissue inﬂammation, ectopic fat depo-
sition and adipose tissue dysfunction. Our study aimed to identify novel metabolic and inﬂammatory
markers in serum and omental adipose tissue which characterize the “unhealthy” obese patients and
distinguish them from obese patients with better metabolic proﬁle.
Design: Cross-sectional study.
Patients: Subjects included 75 obese patients undergoing bariatric surgery at the Tel-Aviv Medical Center
(mean age 43.9  13.9, mean BMI 41  8.4). The HOMA median value was used as a cut-off to differ-
entiate between patients with better or worse insulin resistance.
Measurements: Demographic data, fasting serum insulin, glucose, bile acids, serum metabolic and in-
ﬂammatory markers were obtained. During the bariatric surgery, omental adipose tissue was harvested
and analyzed for metabolic and inﬂammatory markers using qRT-PCR. Logistic regressions were used to
calculate odds ratio and 95% conﬁdence interval for the prediction of the metabolic proﬁle.
Results: Serum markers that were signiﬁcantly higher among the obese with HOMA >6 were total bile
acids. In the omental adipose tissue the inﬂammatory markers TNFa and ADAM17 were signiﬁcantly
higher among obese patients with HOMA >6. In multivariate analysis, the strongest predictor for insulin
resistance was ADAM17 (OR ¼ 1.82, 1.06e3.14, P ¼ 0.031).
Conclusions: The study highlighted the predictive value of serum bile acids in identifying obese patients
at high risk. Secondly, omental adipose tissue ADAM17 was revealed as a novel and strongest inde-
pendent predictor for higher insulin resistance in morbidly obese patients.
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Obesity is associated with increased risk of developing metabolic
syndrome(MetS), type2diabetesmellitus (T2DM)andcardiovascular
disease (CVD) leading to higher all-cause mortality. However, accu-
mulatingevidencesuggests thatnot all obesesubjects areat increased
cardiometabolic risk and that the “metabolically healthy obese”
(MHO) phenotype may exist [1]. These individuals are deﬁned as
having metabolically benign obesity [2] with high levels of insulin
sensitivity, normal lipid and inﬂammation proﬁles and are normo-
tensive, despite excessive body fatness [3e5].
The molecular basis for this phenotype is not well understood
but is likely to involve reduced inﬂammatory responses [6].ts reserved.
Table 1
Characteristics of the study population (mean  SD, unless otherwise
stated)
Characteristic n ¼ 75 Distribution
Age (years) 43.89  13.88
Gender (% men) 30.7
BMI (kg/m2) 41.04  8.36
Diabetes (%) 24.3
Oral diabetic medication (%) 12
HOMA (score) 8.10  7.17
Insulin (mU/ml) 33.81  24.68
ALT (U/l) 14.88  18.49
AST (U/l) 23.07  12.44
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MHO, including lower omental fat accumulation, higher birth
weight, adipose cell size, and gene expression-encoding markers of
adipose cell differentiation [7]. Recent studies suggest that
inﬂammation of omental adipose tissue, ectopic fat deposition and
adipose tissue dysfunction mediate IR in human obesity indepen-
dently of total body fat mass. This suggests that mechanisms
beyond a positive caloric balance, such as inﬂammation and adi-
pokine release determine the pathological metabolic consequences
in patients with obesity [8].
So far, there is still limited data regarding the determinants of
the MHO phenotype, which would shed light on the pathogenesis
of metabolic alterations in obesity and would help in the devel-
opment of new therapeutic interventions tailored to obese in-
dividuals with speciﬁc metabolic phenotype.
In the present study, we aimed to identify inﬂammatory and
metabolic markers in serum and omental adipose tissue of
morbidly obese patients which correlate with better or worse in-
sulin resistance state. In addition, we sought whether there were
any signiﬁcant associations between certain metabolic and in-
ﬂammatory markers.
Experimental design & methods
Study design and population
We have performed cross-sectional study in a cohort of seventy
ﬁve morbidly obese patients attending the obesity clinic at the Tel-
AvivMedical Center and that underwent a bariatric surgery. All data
were collected prospectively. Exclusion criteria were: type-2 dia-
betes treated with insulin and type-1 diabetes. The HOMA was
calculated as fasting serum insulin [mU/ml]  fasting plasma
glucose [mmol/l]/22.5 [9] served in the deﬁnition of the MHO
(divided to percentiles as accepted [1]).
Serum tests
Serum was drawn from fasted patients before their bariatric
surgery and kept frozen in aliquots at 80 C. Serum adipokines
and inﬂammatory cytokines (adiponectin, IL-6, resistin, pro-
granulin) were detected by ELISA assays (R&D systems). Total
glucose dependent insulinotrophic polypeptide (GIP) was detected
by ELISA (EMD Millipore Corporation). Other metabolic and liver
function tests (including bile acids) were assayed at the local
chemistry lab. Insulin was assessed by RIA at the endocrinology lab
at Tel-Aviv Sourasky Medical Center.
Quantitative real time RT-PCR from omental adipose tissue
Omental fat was taken from patients that signed the informed
consent form for fat biopsy (not all subjects that agreed for their
sera to be used agreed to have biopsies of fat taken) during the
bariatric surgery and was used to extract total RNA using the
RNeasy Lipid tissue kit (Qiagen) and 2.5 mg total RNA was reverse-
transcribed using M-MLV (Promega, Madison, WI). Real time RT-
PCR (qRT-PCR) was performed using the Absolute Blue QPCR
SYBR green ROX mix (Thermo Fisher Scientiﬁc, Epsom, Surrey, UK)
in the Corbett rotor light cycler (Corbett Robotics Pty Ltd, Brisbane,
Australia). The primers used were:
Lipoprotein lipase (LPL): 50- GGGCATGTTGACATTTACCC-30, 50-
CTCGTGGGAGCACTTCACTA - 30;
CIDEC: 50- CTGGCAGGGGATACAGTGTT -30, 50-
GTCCTGTGGGTTCAGCTTGT - 30;
CIDEA: 50- CCAACCATGACAGGAGCAG -30, 50- TCTTCCTCCAG-
CACCAGAGT - 30;Perilipin (plin): 5 0- GGAGTACCTCCTCCCTCCAG -3 0, 5 0-
TCTGCACGGTGTATCGAGAG - 3 0;
11b-hydroxysteroid dehydrogenase type 1 (HSD1B11): 50-
AGAGCAATTTGTTGCCCAAG -30, 50- AATGCTTCCATTGCTCTGCT- 30;
Progranulin (PRGN): 50- GCCACTCCTGCATCTTTACC -30, 50-
GATCTTTGGAAGCAGGATCG - 30;
Sortilin: 50- CATTTGGGGCTTCACAGAAT -30, 50-
TTCAGGGTCTGTGGAGTGTG- 30;
IL-6: 50- TACCCCCAGGAGAAGATTCC -30, 50-
TTTTCTGCCAGTGCCTCTTT - 30; GIP receptor (GIPR): 50-CAATGGG-
GACTTTGGAGAGA-30,50-AAGATGAGCAGGGCTAGCAG-30;
TNFa: 50- TCAGCCTCTTCTCCTTCCTG -30, 50- GCCA-
GAGGGCTGATTAGAGA - 30;
ADAM17: 50- GAGGACCAGGGAGGGAAATA -30, 50- CTTCATC-
CACCCTCGAGTTC - 30;
TIMP3: 50- AGGACGCCTTCTGCAACTC -30, 50- CTTCATCTGCTT-
GATGGTGTAG - 30;
Fractalkine: 50- TGTGACGAAATGCAACATCA-30, 50-
CTGTGCTGTCTCGTCTCCAA - 30;
Osteopontin (OPN): 50-GGCTAAACCCTGACCCATCT -30, 50-
GTCAATGGAGTCCTGGCTGT- 30;
CCL2: 50- CCCCAGTCACCTGCTGTTAT -30, 50- AGATCTCCTTGGC-
CACAATG- 30;




IL-1b: 50- CTGTCCTGCGTGTTGAAAGA-30, 50-TTCTGCTTGA-
GAGGTGCTGA-30;
RPLPO: 50- CCCGAGAAGACCTCCTTTTT -30, 50- AGGA-
GAAGGGGGAGATGTTG - 30;Statistical analysis
Statistical analyses were performed using SPSS version 21.
Continuous variables are presented as means  SD.
To test differences in continuous variables between the two
groups of metabolic status, the independent samples t-test and, if
necessary, for non-normally distributed variables, the nonpara-
metric ManneWhitney test were performed (as depicted in
Table 2).
Associations between nominal variables were performed with
the Pearson ChieSquare test. Correlations between continuous
variables were calculated with the Pearson or spearman correla-
tion. A multivariate logistic regression analysis was performed to
test the gender adjusted association between the metabolic and
inﬂammatory parameters and the metabolic phenotype. The vari-
ables that remained signiﬁcantly associated with elevated HOMA
with adjustment for gender, were further tested in an expended
multivariate analysis (with a stepwise entry) aimed to deﬁne the
Table 2
Comparison of patients with HOMA above and below the median (mean  SD, unless otherwise stated)
Variable HOMA below median (<6) HOMA above median (>6) P value
Age (years) 42.45  14.37 (n ¼ 30) 43.45  10.31 (n ¼ 29) 0.762
Gender (% men) 13.3 (n ¼ 30) 51.7 (n ¼ 29) 0.002
BMI (kg/m2) 42.79  7.52 (n ¼ 30) 42.88  6.53 (n ¼ 29) 0.850b
ALT (U/l) 10.63  4.73 (n ¼ 30) 15.50  9.82 (n ¼ 29) 0.021
AST (U/l) 19.93  7.17 (n ¼ 30) 24.34  10.66 (n ¼ 29) 0.066
Diabetes % 20.0 39.3 0.107
HOMA (score) 4.46  1.21 (n ¼ 30) 12.53  9.13 (n ¼ 29) <0.001
Serum markers
IL-6 (pg/ml) 7.22  4.26 (n ¼ 21) 7.09  2.57 (n ¼ 21) 0.905
Resistin (ng/ml) 10.44  4.75 (n ¼ 27) 10.31  5.86 (n ¼ 24) 0.930
Adiponectin (ug/ml) 5.91  4.34 (n ¼ 28) 4.01  2.30 (n ¼ 24) 0.060
Total GIP (pg/ml) 46.39  36.90 (n ¼ 23) 37.10  26.58 (n ¼ 27) 0.763b
Progranulin (ng/ml) 53.75  12.10 (n ¼ 30) 59.17  17.42 (n ¼ 29) 0.172
TG (mg/dl) 146.23  57.66 (n ¼ 30) 190.62  85.99 (n ¼ 29) 0.025
Insulin (mU/ml) 22.27  5.88 (n ¼ 30) 48.72  31.63 (n ¼ 29) <0.001b
Bile acids (mM) 3.17  3.37 (n ¼ 29) 6.22  5.84 (n ¼ 29) 0.003b
Visceral adipose tissue markers (AU)a
Metabolic markers
CIDEA 11.15  9.34 (n ¼ 19) 14.25  16.26 (n ¼ 16) 0.485
CIDEC 3.26  1.83 (n ¼ 19) 4.61  2.57 (n ¼ 16) 0.081
PLIN 7.11  5.10 (n ¼ 19) 7.68  6.23 (n ¼ 15) 0.774
Lipoprotein lipase 1.56  1.25 (n ¼ 20) 2.70  2.88 (n ¼ 16) 0.239b
HSD1B11 45.28  40.72 (n ¼ 14) 42.14  45.10 (n ¼ 15) 0.846
Sortilin 29.83  88.93 (n ¼ 19) 16.41  13.56 (n ¼ 17) 0.222b
GIPR 1.45  1.18 (n ¼ 19) 1.88  1.63 (n ¼ 15) 0.521b
Inﬂammatory markers (AU)a
PRGN 22.92  50.05 (n ¼ 19) 12.03  15.70 (n ¼ 17) 0.692b
FKN 2.67  2.53 (n ¼ 11) 4.44  2.80 (n ¼ 9) 0.156
OPN 8.79  7.95 (n ¼ 12) 14.97  16.26 (n ¼ 12) 0.254
ADAM17 2.38  1.26 (n ¼ 20) 4.30  2.21 (n ¼ 17) 0.004
TIMP3 11.52  6.35 (n ¼ 20) 12.95  7.85 (n ¼ 17) 0.545
TNF-a 3.18  2.66 (n ¼ 20) 9.90  12.65 (n ¼ 16) 0.004b
CCL2 22.73  29.81 (n ¼ 18) 14.70  13.54 (n ¼ 13) 0.689b
CCL8 12.76  15.52 (n ¼ 17) 14.45  12.31 (n ¼ 13) 0.187b
CCL20 13.64  21.23 (n ¼ 15) 16.88  22.26 (n ¼ 10) 0.717
IL-1b 2.74  3.27 (n ¼ 18) 3.52  2.30 (n ¼ 11) 0.498
IL-6 63.81  106.69 (n ¼ 18) 64.12  75.05 (n ¼ 16) 0.629b
Bold values mean signiﬁcance of P < 0.05.
a AU ¼ arbitrary units: Expression of the various genes in visceral adipose tissue was assessed by qRT-PCR and normalized to expression of housekeeping gene RPLPO.
b Calculated by the ManneWhitney test (for all other variables, that had normal distribution, the independent samples t-test was performed).
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P < 0.05 was considered statistically signiﬁcant for all analyses.
Ethics
The study was approved by the Tel-Aviv Sourasky Medical
Center IRB and all patients signed an informed consent.
Results
Characteristics of the study population
Seventy ﬁve patients were included after exclusion of two pa-
tients treated with insulin (mean age 43.9  13.9 years). The ma-
jority of the patients were women (69.3%) and about one quarter
had type-2 diabetes. The characteristics of the study group are
presented in Table 1.
Serum variables associated with lower insulin sensitivity among
obese subjects
For the analysis of parameters of serum and adipose tissue
variables associated with HOMA, 16 patients with BMI <30 were
excluded, leaving 59 patients with BMI >30 and measured HOMA.
The study population was divided into two groups with lower
and higher insulin sensitivity using the median HOMA value of 6.
Importantly, the two groups had very similar age and BMI. Thepercentage of men was signiﬁcantly higher among patients with a
higher HOMA, and thus adjustment for gender was performed
when testing the association with metabolic and inﬂammatory
parameters that were different between groups.
The serum markers tested were several inﬂammatory adipose
tissue derived-cytokines and adipokines, previously shown to be
correlated with metabolic syndrome and insulin resistance [10,11].
However, the well-established serum markers did not differentiate
between the two groups, with the exception of adiponectin, with
levels reduced in the group with HOMA >6, albeit not signiﬁcantly
(P ¼ 0.060) (Table 2).
Strikingly, bile acids levels were almost two-fold higher in group
with HOMA >6 (P ¼ 0.003) (Table 2). Of note, the signiﬁcance was
preserved even after adjustment to gender (OR¼ 1.21, 95% CI: 1.01e
1.45, P ¼ 0.044).
Serum triglycerides were also signiﬁcantly increased in the
group with HOMA >6, but the signiﬁcance was only borderline
after adjustment to gender.Omental adipose tissue inﬂammatory variables associated with
lower insulin sensitivity
Table 2 presents data of omental tissue variables from patients
that agreed to fat biopsies. In addition, values of parameters below
detection levels were not included.
Expression of TNFa, the inﬂammatory cytokine shown to be
associated with inﬂammation-induced insulin resistance two
Table 3
Correlations between inﬂammatory markers in adipose tissue
Correlation FKN OPN CCL8 CCL2 IL1b
OPN r 0.601 1
P 0.001
CCL8 r 0.213 0.313 1
P 0.307 0.112
CCL2 r 0.397 0.301 0.600 1
P 0.049 0.119 <0.001
IL1b r 0.102 0.037 0.546 0.772 1
P 0.645 0.861 <0.001 <0.001
CCL20 r 0.634 0.547 0.265 0.515 0.439
P 0.002 0.005 0.136 0.002 0.015
Bold values mean signiﬁcance of P < 0.05.
M. Khatib et al. / Journal of Clinical & Translational Endocrinology 1 (2014) 115e119118decades ago [12], was indeed three-time higher (P ¼ 0.004) in the
omental fat of the lower insulin sensitivity group (Table 2). Its
signiﬁcance was preserved after adjustment to gender (OR ¼ 1.38,
1.04e1.84, P ¼ 0.026).
A new player in obesity induced-insulin resistance is the
enzyme ADAM17 [13], which among other substrates, cuts and
releases the mature TNFa into the circulation [13]. Levels of
ADAM17 mRNA were almost two-fold higher in the group with
lower insulin sensitivity (P ¼ 0.004) (Table 2) and the association
remained signiﬁcant after adjustment for gender (OR ¼ 1.93, 1.09e
3.40, P ¼ 0.024).
Importantly, when the variables that remained signiﬁcantly
associated with elevated HOMA with adjustment for gender were
further tested together in a stepwise logistic regression, the
strongest predictor that remained in the model was ADAM17
(OR ¼ 1.82, 1.06e3.14, P ¼ 0.031).
Analysis of inﬂammatory cytokines and chemokines in omental
adipose tissue revealed strong positive correlations between two
macrophage adhesion molecules, FKN and osteopontin (OPN)
(Table 3). This association become even stronger (r ¼ 0.916,
P ¼ 0.001) when analysis was performed in the group with the
lower insulin sensitivity. A remarkable signiﬁcant positive corre-
lation between levels of the two macrophage recruitment chemo-
kines CCL2 and CCL8 and the inﬂammatory cytokine IL-1b was also
observed (Table 3). The novel adipokine CCL20 [14] was also
signiﬁcantly positively correlated with the inﬂammatory cytokines
and chemokines in omental adipose tissue (Table 3).
Lipid droplets proteins regulate the capacity of adipocytes to
esterify fatty acids into triglycerides and store themwithin the cell in
a safe manner [15]. Previous studies showed that higher expression
of lipid droplet proteins perilipin, CIDEA and CIDEC were associated
with higher insulin sensitivity in obese patients with similar BMI
[16]. However, we have found no signiﬁcant differences in theFigure. 1. Correlations between: (A) mRNA expression of PRGN and IL-6 (n ¼ 45); (B) PRGN
patients. Expression of PRGN, sortilin and IL-6 was detected by qRT-PCR and normalized toexpression of lipid droplet proteins or in TG uptake enzyme lipo-
protein lipase in the omental adipose tissue of both groups (Table 2).
Correlation between omental adipose tissue PRGN, sortilin and IL-6
The novel adipokine PRGN has been shown to increase insulin
resistance via induction of adipose tissue IL-6 [17]. Indeed, we have
found a very strong positive correlation between omental adipose
tissue expression of PRGN and IL-6 (Fig. 1). The trafﬁcking molecule
sortilin is known to regulate serum levels of PRGN by internalizing
it and directing it to degradatory pathways [18]. For the ﬁrst time,
we show a strong positive correlation between the mRNA levels of
these three factors in omental adipose tissue (Fig. 1). Of note, these
correlations become even stronger in the group with lower HOMA:
mRNA expression of PRGN and IL-6 (r ¼ 0.95, P < 0.001, n ¼ 22);
PRGN and sortilin (r ¼ 0.96, P < 0.001, n ¼ 24); sortilin and IL-6
(r ¼ 0.93, P < 0.001, n ¼ 22).
Discussion
The present study highlighted the important role of serum bile
acids as predictors of increased IR among morbidly obese patients.
Furthermore, our results revealed ADAM17 as a novel and stron-
gest predictor of IR in omental adipose tissue of morbidly obese
patients.
Bile acids have beneﬁcial effects on triglyceride metabolism and
improve insulin sensitivity and whole body glucose homeostasis
[19,20]. Indeed, post-prandial serum bile acids were found to be
increased after Roux-en-Ygastric bypass [21]. Furthermore, the role
of bile acids as general metabolic integrators was shown in a mu-
rine model in which bile acids administration increased energy
expenditure of brown fat and prevented obesity and IR [22]. Sur-
prisingly, our studies demonstrated increased levels of fasting bile
acids in the group with lower insulin sensitivity (Table 2). These
results of higher basal serum bile acidsmay reﬂect the impaired bile
acids secretory function found in fatty liver disease [23]. Consistent
with our results, serum bile acids were previously shown to be
increased in diabetic obese patients [24].
In adipose tissue, the lower insulin sensitivity group displayed
increased mRNA levels of inﬂammatory and metabolic markers.
Numerous studies have highlighted the role of adipose tissue
inﬂammation in obesity and IR [25e27].
Studies performed two decades ago recognized TNFa as a pivotal
non-dispensable player in obesity-induced inﬂammation and IR
[26,27]. The TACE/ADAM17 enzyme was shown to induce the
shedding of TNFa, therefore participating in IR induction. A large
body of evidence suggests that ADAM17 is activated in metabolic
disorders and contributes to progressive deterioration of metabolicand sortilin (n ¼ 49); (C) sortilin and IL-6 (n ¼ 45) in omental adipose tissue of obese
expression of RPLPO.
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inﬁltration by macrophages, reduction of glucose uptake in skeletal
muscle and increased lipogenesis in the liver [13]. In our study, a
stepwise logistic regression analysis of the variables signiﬁcantly
associated with elevated HOMA revealed that the strongest pre-
dictor for IR was ADAM17, with almost two-fold increased odds per
one unit increase in ADAM17 levels. Furthermore, as expected,
adipose tissue TNFa mRNA expression was another inﬂammatory
marker associated with higher IR.
PRGN is an ubiquitously secreted protein, playing roles in cancer,
wound healing and neurodegeneration [17,18,28]. Importantly, it
was recently identiﬁed as a novel adipokine that participates in the
induction of IR via increased IL-6 secretion [17]. Indeed, our analysis
of adipose tissue showed a strong association between mRNA
expression of PRGN, IL-6 and also sortilin (Fig. 1). Sortilin, a traf-
ﬁcking molecule, regulates serum PRGN levels by directing it for
degradation [29]. Here for the ﬁrst time, we show an association
between adipose tissue mRNA levels of sortilin and PRGN. Previous
studies also support the concept of PRGN in IR, since elevated serum
PRGN were associated with high levels of serum glucose and with
omental obesity [30,31]. However, in our studies, we did not ﬁnd
any signiﬁcant difference in serum PRGN levels in the twomorbidly
obese groups.
FKNandOPN, two chemokines involved inmonocyte recruitment
and adhesion and previously shown to be involved in IR [30e33],
showed a two-fold increase in theirmRNAexpression in the omental
adipose tissue of the morbidly obese patients with the lower insulin
sensitivity, however this increase did not reach statistical signiﬁ-
cance, due maybe to the low number of subjects (Table 2). Notably,
the expression of FKN was strongly associated with expression of
OPN, and this association became even stronger in the group with
lower insulin sensitivity (r ¼ 0.916, P ¼ 0.001).
Our study is limited by the fact that patients were recruited from
the bariatric surgery clinic and all of them had some degree of IR,
and therefore our cut-off was arbitrarily determined according to
the median value of HOMA. Despite the markedly different HOMA
averages of the two groups (4.46  1.20 vs 12.53  9.13), a study
using “healthy obese patients” with HOMA <2 may reveal stronger
differences between the groups. Another limitation stems from the
cross-sectional design of the study that prevents us from inferring
the direction of the associations presented in this study.
Conclusions
Our study has examined several novel predictors of IR in
morbidly obese patients, including serum bile acids and ADAM17,
which may serve both as diagnostic markers and also may become
useful targets for treatment of the metabolic syndrome in obese
patients.
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